What Did This CEO Just Do with Personal Shares of Oramed Pharmaceuticals (NASDAQ: ORMP)?

By Carrie Williams

Today, the President & CEO of Oramed Pharmaceuticals (NASDAQ: ORMP), Nadav Kidron, sold shares of ORMP for $364.

This is Kidron’s first Sell trade following 4 Buy transactions.

See today’s analyst top recommended stocks >>

Currently, Oramed Pharmaceuticals has an average volume of 54.55K.

In the last 30 days, insiders have sold $364 worth of ORMP shares and purchased $721 worth of ORMP shares.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.